One of the questions I’m asked most frequently about Calmare Pain Therapy Treatment is why did we choose it for our practice? My team and I spent years researching, interviewing and visiting manufacturers who produce technology to alleviate chronic pain. One of the decisive factors was a scientific report published last year by Thomas J. Smith, MD, Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit at Virginia Commonwealth University’s Massey Cancer Center.
The study, one of the first detailed studies conducted in the United States since FDA clearance, concluded, “Patient-specific cutaneous electrostimulation with the MC5-A Calmare device appears to dramatically reduce pain in refractory CIPN patients with no toxicity.” CIPN, a debilitating side effect for 30 – 40 percent of cancer patients, causes sharp ongoing pain in the hands and feet and affects an estimated four million cancer patients in the United States alone.
Their specific findings:
· Calmare Pain Therapy Treatment relieved refractory (resistant) CIPN pain quickly and significantly, with virtually no side effects.
- Patients experienced a 64% reduction in pain, on average.
- Four of 16 patients had a complete disappearance of pain.
- Some patients had return of complete or partial normal sensation and relief of numbness, as well as relief of pain.
- Some pain relief is durable for months but may require re-treatment and maintenance.
For those of us with expertise in pain management, these data findings are astounding. We learned that Calmare could be equally successful in the treatment of other types of chronic pain that are resistant to traditional therapy and medication, such as:
· Neck and back pain
· Pain as a result of other chronic diseases
As the first and only pain treatment facility in New Jersey, and one of fewer than 20 in the nation to offer Calmare, we know firsthand this therapy can be successful for many, many pain sufferers.
Just a few months ago, the Mayo Clinic announced it would launch its own Calmare study, and we look forward to sharing their findings with you as well.
Dr. Michael Cooney
Rutherford Allied Medical Group